PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V3024 - Common Stock
Taking everything into account, CATX scores 3 out of 10 in our fundamental rating. CATX was compared to 571 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. CATX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CATX has reported negative net income.
CATX had a negative operating cash flow in the past year.
CATX had negative earnings in each of the past 5 years.
CATX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CATX (-20.95%) is better than 76.90% of its industry peers.
Looking at the Return On Equity, with a value of -23.71%, CATX belongs to the top of the industry, outperforming 83.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.95% | ||
| ROE | -23.71% | ||
| ROIC | N/A |
ROA(3y)-21.2%
ROA(5y)-31.63%
ROE(3y)-26.25%
ROE(5y)-41.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CATX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, CATX has less shares outstanding
CATX has a worse debt/assets ratio than last year.
2.2 Solvency
CATX has an Altman-Z score of 2.71. This is not the best score and indicates that CATX is in the grey zone with still only limited risk for bankruptcy at the moment.
CATX has a better Altman-Z score (2.71) than 74.43% of its industry peers.
CATX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CATX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
CATX has a Current Ratio of 27.73. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
CATX has a Current ratio of 27.73. This is amongst the best in the industry. CATX outperforms 97.53% of its industry peers.
A Quick Ratio of 27.73 indicates that CATX has no problem at all paying its short term obligations.
CATX has a Quick ratio of 27.73. This is amongst the best in the industry. CATX outperforms 97.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 27.73 | ||
| Quick Ratio | 27.73 |
3. Growth
3.1 Past
The earnings per share for CATX have decreased strongly by -25.00% in the last year.
The Revenue has been growing slightly by 7.46% in the past year.
Measured over the past years, CATX shows a quite strong growth in Revenue. The Revenue has been growing by 17.80% on average per year.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y17.8%
Sales Q2Q%-83.11%
3.2 Future
CATX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -121.90% yearly.
Based on estimates for the next years, CATX will show a small growth in Revenue. The Revenue will grow by 4.86% on average per year.
EPS Next Y-2619.93%
EPS Next 2Y-315.34%
EPS Next 3Y-180.72%
EPS Next 5Y-121.9%
Revenue Next Year-25.94%
Revenue Next 2Y-67.41%
Revenue Next 3Y-60.63%
Revenue Next 5Y4.86%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CATX's earnings are expected to decrease with -180.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-315.34%
EPS Next 3Y-180.72%
5. Dividend
5.1 Amount
No dividends for CATX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PERSPECTIVE THERAPEUTICS INC
NYSEARCA:CATX (11/22/2024, 8:04:02 PM)
After market: 3.51 +0.04 (+1.15%)3.47
+0.47 (+15.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap233.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.95% | ||
| ROE | -23.71% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 27.73 | ||
| Quick Ratio | 27.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2619.93%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y